Aspirin for the Primary Prevention of Cardiovascular Diseases in Patients with Chronic Kidney Disease: An Updated Meta-analysis

ConclusionsRCT evidence points to a possible benefit in cardiovascular event reduction from aspirin administration, at the cost of increased major bleeding risk. This finding was not confirmed when the existing observational evidence was incorporated. Further research should determine the most appropriate subpopulation of chronic kidney disease patients that would benefit the most from prophylactic aspirin therapy.Registration The study protocol has been prospectively registered and is publicly available from:https://doi.org/10.17504/protocols.io.261ged63jv47/v1.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research